NCT07123415View on ClinicalTrials.gov

A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

October 31, 2028

Study Completion Date

December 31, 2028

Conditions
Advanced Solid CancerAdvanced Solid Tumor (Phase 1)
Interventions
DRUG

APX-343A

Oral administration twice daily

DRUG

Pembrolizumab

intravenous \[IV\]

Sponsors
All Listed Sponsors
lead

Aptabio Therapeutics, Inc.

INDIV